Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Ischemic strokes occur when there is blocked blood flow to the brain, something that can result in permanent disability. Doctors can use certain medications to dissolve blood clots when they are the ...

A trial of tenecteplase in patients who had stroke symptoms when they awoke, but who were not selected on the basis of CT perfusion imaging or perfusion–diffusion MRI, showed that tenecteplase therapy ...

Ninety-day mortality was 5.0 and 3.2% with tenecteplase and standard medical treatment, respectively. HealthDay News — For patients with non-large vessel occlusion acute ischemic stroke and ...

Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion does not improve vision recovery at 30 days compared with oral aspirin, according to a study ...

For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later ...

Intravenous tenecteplase (TNKase) before endovascular thrombectomy improved outcomes for acute ischemic stroke patients who presented within 4.5 hours after onset in a randomized trial from China. The ...

More patients receiving tenecteplase versus standard medical treatment had excellent functional outcome at 90 days. (HealthDay News) — For patients with non-large vessel occlusion acute ischemic ...